TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07028632: A Phase I/II Study to Assess the Safety, Tolerability and Efficacy of NouvNeu001 Injection for Mid- to Late-stage Parkinson's Disease

Sponsor: iRegene Therapeutics Co., Ltd. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07028632 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07028632 Rescue Dossier →